Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title Hits
11 Mar 2010 Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies 1
09 Mar 2010 Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction 14
08 Mar 2010 Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx 12
03 Mar 2010 Novo Nordisk receives FDA approval for Norditropin FlexPro for growth hormone treatment (3 March 2010) 7
03 Mar 2010 Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly 154
01 Mar 2010 FDA Accepts VIAject(R) NDA for Review 30
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) 49
23 Feb 2010 Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297 17
22 Feb 2010 Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity 11
17 Feb 2010 Marcadia Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701 41
14 Feb 2010 Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a Toll-like Receptor Antagonist at Keystone Symposium 32
11 Feb 2010 Roche study drug may offer valuable new treatment option for patients with type 2 diabetes 16
11 Feb 2010 Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naļve Patients with Type 1 Gaucher Disease 14
11 Feb 2010 Two-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints 15
11 Feb 2010 Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium 15
11 Feb 2010 Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease 13
10 Feb 2010 Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint 10
09 Feb 2010 XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients 15
09 Feb 2010 Penwest Initiates Second Phase IIa Clinical Trial for A0001 20
09 Feb 2010 Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease 14
08 Feb 2010 Resverlogix Completes Patient Recruitment for ASSERT Trial 31
05 Feb 2010 BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA 19
05 Feb 2010 CREON(R) (pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption in Children with Cystic Fibrosis, Study in Clinical Therapeutics Reports 25
02 Feb 2010 Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease 59
28 Jan 2010 Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatide 24
28 Jan 2010 GFT505 Positioned as a Leading Drug Candidate in its Therapeutic Area 56
26 Jan 2010 Envoy Enters Diabetes and Obesity Collaboration with Merck & Co., Inc. 40
26 Jan 2010 Novo Nordisk receives US approval for Victoza (liraglutide) for the treatment of type 2 diabetes 20
26 Jan 2010 Alizé Pharma signs research collaboration and license option agreement with Lilly 112
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1514

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics